Bailard Inc. Grows Holdings in Dynavax Technologies Co. (DVAX)
Bailard Inc. grew its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 333.3% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 195,000 shares of the biopharmaceutical company’s stock after purchasing an additional 150,000 shares during the period. Bailard Inc.’s holdings in Dynavax Technologies were worth $2,418,000 as of its most recent SEC filing.
A number of other large investors have also recently added to or reduced their stakes in the business. JPMorgan Chase & Co. lifted its stake in Dynavax Technologies by 1.8% during the third quarter. JPMorgan Chase & Co. now owns 264,669 shares of the biopharmaceutical company’s stock worth $3,282,000 after purchasing an additional 4,591 shares in the last quarter. Wells Fargo & Company MN lifted its stake in Dynavax Technologies by 6.0% during the third quarter. Wells Fargo & Company MN now owns 87,721 shares of the biopharmaceutical company’s stock worth $1,087,000 after purchasing an additional 4,979 shares in the last quarter. Patriot Financial Group Insurance Agency LLC lifted its stake in Dynavax Technologies by 39.2% during the third quarter. Patriot Financial Group Insurance Agency LLC now owns 29,170 shares of the biopharmaceutical company’s stock worth $362,000 after purchasing an additional 8,220 shares in the last quarter. Alps Advisors Inc. lifted its stake in Dynavax Technologies by 11.2% during the second quarter. Alps Advisors Inc. now owns 90,375 shares of the biopharmaceutical company’s stock worth $1,378,000 after purchasing an additional 9,103 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new position in Dynavax Technologies during the third quarter worth $131,000. Institutional investors own 76.73% of the company’s stock.
DVAX has been the topic of a number of research reports. Cantor Fitzgerald restated a “buy” rating and set a $30.00 price target on shares of Dynavax Technologies in a research note on Monday, October 1st. ValuEngine upgraded Dynavax Technologies from a “sell” rating to a “hold” rating in a research note on Tuesday, October 23rd. BidaskClub cut Dynavax Technologies from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 18th. Cowen reiterated a “buy” rating and issued a $30.00 price objective on shares of Dynavax Technologies in a research note on Monday, October 22nd. Finally, Zacks Investment Research upgraded Dynavax Technologies from a “sell” rating to a “hold” rating in a research note on Thursday, August 9th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. Dynavax Technologies currently has an average rating of “Hold” and an average price target of $28.00.
Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings data on Monday, November 5th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.08). The company had revenue of $1.46 million during the quarter, compared to analyst estimates of $3.16 million. Dynavax Technologies had a negative net margin of 5,044.85% and a negative return on equity of 97.79%. The firm’s revenue was up 2822.0% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.38) earnings per share. As a group, analysts anticipate that Dynavax Technologies Co. will post -2.51 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Bailard Inc. Grows Holdings in Dynavax Technologies Co. (DVAX)” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://www.watchlistnews.com/bailard-inc-grows-holdings-in-dynavax-technologies-co-dvax/2663728.html.
About Dynavax Technologies
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.
Further Reading: Asset Allocation, Balancing Your Investments
Want to see what other hedge funds are holding DVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dynavax Technologies Co. (NASDAQ:DVAX).
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.